The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesICC/IF: Use at an assay dependent dilution (PMID 19324423).
IHC-P: Use at an assay dependent concentration.
IHC-Fr: Use at an assay dependent concentration.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionComplexes with metalloproteinases (such as collagenases) and irreversibly inactivates them by binding to their catalytic zinc cofactor. May form part of a tissue-specific acute response to remodeling stimuli. Known to act on MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, MMP-14 and MMP-15.
Involvement in diseaseDefects in TIMP3 are the cause of Sorsby fundus dystrophy (SFD) [MIM:136900]. SFD is a rare autosomal dominant macular disorder with an age of onset in the fourth decade. It is characterized by loss of central vision from subretinal neovascularization and atrophy of the ocular tissues. Generally, macular disciform degeneration develops in the patients eye within 6 months to 6 years.
Sequence similaritiesBelongs to the protease inhibitor I35 (TIMP) family. Contains 1 NTR domain.
Cellular localizationSecreted > extracellular space > extracellular matrix.
Hurst LA et al. Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment. J Neuroimmunol210:108-12 (2009).
Read more (PubMed: 19324423) »
Sun X et al. Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol207:91-101 (2005).
Read more (PubMed: 16007577) »